Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26874136 | 0.84 | NPC1 (0.44) | RAB9ANPC1S1PR1TDP1L3MBTL1 | |
| SCHEMBL27033433 | 0.81 | NPC1 (0.41) | RAB9ANPC1S1PR1TDP1IDO1 | |
| SCHEMBL30365932 | 0.80 | NPC1 (0.50) | RAB9ANPC1TDP1IDO1TDO2 | |
| SCHEMBL24204595 | 0.80 | NPC1 (0.50) | RAB9ANPC1TDP1IDO1TDO2 | |
| SCHEMBL27033328 | 0.79 | NPC1 (0.41) | RAB9ANPC1S1PR1TDP1IDO1 | |
| SCHEMBL24204592 | 0.78 | NPC1 (0.40) | RAB9ANPC1S1PR1TDP1IDO1 | |
| SCHEMBL30389777 | 0.78 | NPC1 (0.40) | RAB9ANPC1S1PR1TDP1IDO1 | |
| Trifluoroacetic Acid SCHEMBL29493151 | 0.75 | CACNA1B (0.40) | RAB9ANPC1CA2L3MBTL1IDO1 | |
| SCHEMBL31010848 | 0.75 | NPC1 (0.46) | RAB9ANPC1TDP1IDO1TDO2 | |
| SCHEMBL27253275 | 0.75 | NPC1 (0.46) | RAB9ANPC1TDP1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069585-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | Dermavant Sciences GmbH (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2025-09-11 | — | — | US | disclosed |
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024050434-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | Dermavant Sciences GmbH (CH) | 2024-03-07 | — | — | WO | disclosed |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2023-11-28 | — | — | US | disclosed |
| EP-4185566-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AHR IMBALANCE | Dermavant Sciences GmbH (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20230124135-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2023-04-20 | — | — | US | disclosed |
| US-11548853-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2023-01-10 | — | — | US | disclosed |
| US-20220153703-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11267788-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124135-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-12252471-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-20250282730-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-20260069585-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | HRH2, AHR, HRH1 | RAB9A 843/4885NPC1 1725/4885CA2 1036/4885 |
| US-20220153703-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-11548853-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
| US-11267788-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | RAB9A 2589/4885NPC1 767/4885CA2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.